Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 46 | 3,260 | 46% |
| 2020 | 30 | 2,624 | 48% |
| 2021 | 43 | 2,939 | 51% |
| 2022 | 30 | 2,883 | 53% |
| 2023 | 30 | 2,932 | 55% |
| 2024 | 38 | 3,138 | 57% |
| 2025 from claims | – | 3,425 3,143–3,623 | 58% |
| 2026 forecast | – | 3,519 3,097–4,061 | 58% |
| 2027 forecast | – | 3,602 3,079–4,292 | 59% |
| 2028 forecast | – | 3,685 3,075–4,512 | 59% |
| 2029 forecast | – | 3,770 3,079–4,727 | 60% |
| 2030 forecast | – | 3,855 3,089–4,941 | 60% |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 48% of the cases CMS names in New York; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 7% inpatient hospital, 85% hospital outpatient, 8% surgery center. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.1 | 8% | 3,450 in 2030+2.8%/yr |
| Massachusetts | 30 | 1,885+3.7%/yr | +3.7%/yr | 2.0 | 1% | 2,140 in 2030+2.1%/yr |
| New Jersey | 26 | 1,784−4.1%/yr | −4.1%/yr | 1.7 | 9% | 1,880 in 2030+0.9%/yr |
| Connecticut | 11 | 668+0.3%/yr | +0.3%/yr | 2.0 | 0% | 740 in 2030+1.6%/yr |
| New Hampshire | 5 | 344−2.3%/yr | −2.3%/yr | 1.5 | 0% | 460 in 2030+4.9%/yr |
| Rhode Island | 2 | 201+0.4%/yr | +0.4%/yr | 2.2 | 31% | 130 in 2030−7.5%/yr |
| Maine | 2 | 101−14%/yr | −14%/yr | 0.6 | 0% | 40 in 2030−13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 98 | 8,386−6.8%/yr | −6.8%/yr | 4.61.1× | 43% | 8,420 in 2030+0.1%/yr |
| Kidney stone management | 134 | 7,123−2.3%/yr | −2.3%/yr | 4.00.6× | 10% | 7,020 in 2030−0.2%/yr |
| Hysterectomy, hysteroscopy & ablation | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.71.1× | 30% | 6,960 in 2030+2.2%/yr |
| Prostatectomy & nephrectomy | 33 | 2,271−2.4%/yr | −2.4%/yr | 1.41.3× | 0% | 2,710 in 2030+3%/yr |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Boston Scientific leads with 49% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 12 companies reported engagement with New York’s surgeons worth $723K in consulting, speaking, meals and travel tied to these products, about $19K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.